RxDoctor Payments Data

John Banzer, MD

Cardiovascular Disease · Silverdale, WANPI 1912933375

Payments from drug & device makers

$10,332in general payments, 2019–2025

Across 618 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • Amgen$1K
  • E.r. Squibb & Sons, L.L.C.$874
  • AstraZeneca$849
  • Novo Nordisk$801
  • Novartis$772
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$10,27099%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,332 in reported general payments places this provider in the 80th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$364,007
Medicare patients
1,211
Services billed
5,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban463$605,031
XareltoRivaroxaban164$226,048
JardianceEmpagliflozin115$144,272
Repatha SureclickEvolocumab59$56,620
EntrestoSacubitril/Valsartan29$42,884
Metoprolol Succinate866$16,110
FarxigaDapagliflozin Propanediol11$12,970
Isosorbide Mononitrate ErIsosorbide Mononitrate638$10,948
DapagliflozinDapagliflozin Propanediol13$6,150
Ranolazine ErRanolazine58$6,054
Atorvastatin Calcium390$3,959
Amiodarone Hcl129$3,582
Rosuvastatin Calcium186$3,414
Verapamil ErVerapamil Hcl37$3,116
Furosemide427$2,801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$598$605,031463 claims
Johnson & JohnsonXarelto$239$226,048164 claims
Boehringer IngelheimJardiance$1,514$144,272115 claims
NovartisEntresto$772$42,88429 claims
AstraZenecaFarxiga$849$12,97011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Silverdale

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →